- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Thrombolysis for acute ischaemic stroke: current status and future perspectives. (Pubmed Central) - Apr 18, 2023
The growing implementation of mobile stroke units and advanced neuroimaging could boost the number of patients who can receive intravenous thrombolysis by shortening onset-to-treatment times and identifying patients with salvageable penumbra. Continued improvements in this area will be essential to facilitate the ongoing research endeavors and to improve delivery of new interventions.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New trial: DIVAr (clinicaltrials.gov) - Apr 12, 2023
P=N/A, N=300, Not yet recruiting,
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Journal: Comparison of dosing errors between tenecteplase and alteplase for management of acute ischemic stroke. (Pubmed Central) - Apr 4, 2023
Tenecteplase was associated with shorter door to needle times, which may be caused by simpler administration times. Institutions could consider strategies to mitigate dosing errors for thrombolytic therapies.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: In Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke. (Pubmed Central) - Mar 30, 2023
While tenecteplase and alteplase have very similar thrombolysis efficacy, tenecteplase has a lower risk of ICH and better resistance to PAI-1. Among the four simulated drugs, reteplase has the slowest fibrinolysis rate, but fibrinogen concentration in systemic plasma is unaffected during thrombolysis.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Magnetic Response Combined with Bioactive Ion Therapy: A RONS-Scavenging Theranostic Nanoplatform for Thrombolysis and Renal Ischemia-Reperfusion Injury. (Pubmed Central) - Mar 29, 2023
Herein, a multifunctional therapeutic nanoparticle (NP) based on FeO and strontium ions encapsulated in mesoporous polydopamine was successfully constructed and then loaded with TNK-tPA (FeM@Sr-TNK NPs)...Then, renal IRI-induced functional metabolic disorder and tissue damage were evidently attenuated by scavenging toxic reactive oxygen and nitrogen species and through the protective effects of bioactive ion therapy, including reduced apoptosis, increased angiogenesis, and inhibited fibrosis. In brief, we constructed a multifunctional nanoplatform for integrating a "diagnosis-therapy-protection" approach to achieve comprehensive management from thrombus to renal IRI, promoting the advancement of related technologies.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: Complications of Intravenous Tenecteplase Versus Alteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 25, 2023
In brief, we constructed a multifunctional nanoplatform for integrating a "diagnosis-therapy-protection" approach to achieve comprehensive management from thrombus to renal IRI, promoting the advancement of related technologies. Across medium- and low-dose tiers, the risks of complications were generally comparable between those treated with tenecteplase versus alteplase for acute ischemic stroke.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
The Contrast Between Stroke and Stroke Mimics (Walter E. Washington Convention Center, Area I, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_6637;
In the absence of major contraindications, he was given tenecteplase (TNK)...Management is supportive with intravenous hydration, corticosteroids and anticonvulsants in case of seizures. CIE should therefore be remembered as an important differential alongside stroke.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Treatment of acute stroke: Current practices and future horizons. (Pubmed Central) - Mar 21, 2023
Endovascular thrombectomy (EVT) has shown considerable efficacy for treating large-vessel occlusions and using CTP, patients can be selected for hours after symptom-onset if viable tissue remains. Further research is underway to determine if EVT can be used for medium vessel occlusions and for basilar artery thromboses as well as to determine whether an "EVT-alone" strategy is superior to "tPA + EVT" strategy.
- |||||||||| Aggrastat (tirofiban) / Correvio, Medicure, Kengreal (cangrelor) / Chiesi, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal, Surgery: Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey. (Pubmed Central) - Mar 16, 2023
This nationwide survey highlights the important heterogeneity in clinical practices across centers. There is a pressing need for trials and guidelines to further evaluate and harmonize antithrombotic regimens in the neurointerventional field.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials. (Pubmed Central) - Mar 15, 2023
There is a pressing need for trials and guidelines to further evaluate and harmonize antithrombotic regimens in the neurointerventional field. TNK in the dose of 0.25
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Thrombolytic Therapy for Non-arteritic Central Retinal Artery Occlusion in an Academic Multi-site Stroke Center (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4359;
11/20 (55%) received additional therapies (ocular massage, intraocular pressure lowering drops, diuretics, intra-arterial verapamil)...Most received a combination of thrombolytic and other conventional therapies, hence thrombolysis-specific outcomes could not be described. Prospective studies comparing thrombolysis and placebo are warranted to guide hyperacute CRAO practice.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Tenecteplase versus alteplase safety and efficacy in acute ischemic stroke: a systematic review and meta-analysis of 3706 patients. (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4352;
However, mortality, recanalization rate, major neurological improvement, symptomatic intracranial hemorrhage, and poor recovery were significant after sensitivity analysis in a dose-dependent manner. Further studies with multiple doses are recommended to support these results.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Iron Deficiency Anemia and Ischemic Stroke in Premenopausal Women (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4235;
Conclusions Iron deficiency anemia may be an important yet under-recognized risk factor for acute ischemic stroke and should be treated aggressively in premenopausal women. Further studies are warranted.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
The Gummies Strike Again: An Emerging Stroke Mimic in New York City (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3883;
One patient received tenecteplase and was admitted to NeuroICU for disabling vertigo and truncal ataxia...This appears to be an occupational hazard for housekeeping staff. Public health campaigns should encourage the proper storage and disposal of THC products.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Large Vessel Occlusion Related Ischemic Stroke From Vitamin B12-Deficiency Related Homocysteine (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2874;
Public health campaigns should encourage the proper storage and disposal of THC products. Patient received thrombolysis with Tenecteplase (TNK) and was emergently taken for mechanical-thrombectomy...Patient was treated with dual antiplatelet therapy with aspirin 81mg , clopidogrel 75mg and initiated on B12 and folate supplements...It is worthwhile to consider vitamin-supplementation with folic-acid (2.5 mg) and B-complex vitamin (50 mg B6 and 1 mg B12) 1
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Tenecteplase Versus Alteplase for Acute Ischemic Stroke in a Community Hospital Setting (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2850;
Patient received thrombolysis with Tenecteplase (TNK) and was emergently taken for mechanical-thrombectomy...Patient was treated with dual antiplatelet therapy with aspirin 81mg , clopidogrel 75mg and initiated on B12 and folate supplements...It is worthwhile to consider vitamin-supplementation with folic-acid (2.5 mg) and B-complex vitamin (50 mg B6 and 1 mg B12) 1 Mortality in the tenecteplase group and no thrombolytic groups was 2%, compared to 3% in the alteplase group.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
BEFAST Assessment in a Rural Community Hospital - the BIRCH Study (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2565;
Secondary outcomes were treatment with tenecteplase and thrombectomy, door to needle time, and door to transfer time...Conclusions Although BEFAST can be successfully utilized in the rural hospital emergency department, utilization does not always result in activation of the acute stroke order set. Reasons for failure to activate the acute stroke order set in the rural ED need to be elucidated.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion date, Trial primary completion date: ORIGINAL: A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (clinicaltrials.gov) - Mar 8, 2023
P3, N=1490, Recruiting,
Reasons for failure to activate the acute stroke order set in the rural ED need to be elucidated. Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2023 --> Oct 2023
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion: TIMELESS: Tenecteplase in Stroke Patients Between 4.5 and 24 Hours (clinicaltrials.gov) - Mar 8, 2023
P3, N=452, Completed,
Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2023 --> Oct 2023 Active, not recruiting --> Completed
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Retrospective data: Comparative Efficacy and Safety of Thrombolytic Agents for Pulmonary Embolism: A Bayesian Network Meta-Analysis. (Pubmed Central) - Mar 7, 2023
Tenecteplase did not reduce mortality compared with anticoagulants alone and may not be a good choice of thrombolytic agent due to an increase in minor bleeding compared with streptokinase and anticoagulants alone. Thrombolytic drugs should be rationally selected to optimize the thrombolytic regimen and achieve as good a balance as possible between thrombolysis and bleeding.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Advances in the management of acute ischemic stroke. (Pubmed Central) - Mar 6, 2023
These data along with the practical advantages of TNK have resulted in a shift to replace intravenous TNK as the standard for thrombolysis. Ongoing studies of IVT with TNK are focussed on defining the optimal dose, expanding the time window with multimodal imaging and defining the role of thrombolysis for bridging patients with stroke due to large vessel occlusion.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
P3 data, Journal, Head-to-Head: Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. (Pubmed Central) - Mar 2, 2023
P3
No abstract available Tenecteplase was non-inferior to alteplase in people with ischaemic stroke who were eligible for standard intravenous thrombolytic but ineligible for or refused endovascular thrombectomy.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Tenecteplase Improves Reperfusion Across Time in Large Vessel Stroke. (Pubmed Central) - Mar 2, 2023
Prethrombectomy reperfusion is associated with better clinical outcomes. ANN NEUROL 2023;93:489-499.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Platelet-targeted thrombolysis for treatment of acute ischemic stroke. (Pubmed Central) - Feb 27, 2023
The tail bleeding time, blood clearance, and biodistribution were then determined to inform the use of SCE5-scuPA in mouse models of photothrombotic stroke and middle cerebral artery occlusion against tenecteplase...In MCAo, SCE5-scuPA did not worsen stroke outcomes or caused ICH, and protected the BBB. Our findings support the ongoing development of platelet-targeted thrombolysis with SCE5-scuPA as a novel emergency treatment for AIS with a promising safety profile.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: Tenecteplase vs. alteplase for treatment of acute ischemic stroke: A systematic review and meta-analysis of randomized trials. (Pubmed Central) - Feb 10, 2023
Further analysis comparing dosing of tenecteplase (0.1, 0.25, 0.32, and 0.4 mg/kg) yielded no significant differences for any of the endpoints (mRS 0-1, mRS 0-2, sICH, and mortality) compared to alteplase. Based on available evidence from completed RCTs, tenecteplase has proven similar safety and efficacy to alteplase for treatment of AIS.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Intravenous Thrombolysis In Combination With Mechanical Thrombectomy: An Updated Meta-Analysis Of Clinical Trials (Hall F, Poster Hall; P142) - Feb 7, 2023 - Abstract #ISC2023ISC_1649;
Our results did not favor either IVT+MT or MT alone in terms of clinical outcomes and complications. However, more trials are needed to further compare both approaches and to evaluate the impact of certain factors on this comparison such as MT technique (Stent Retriever versus Aspiration), LVO location, and the used thrombolytic agent (Alteplase versus Tenecteplase).
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Door To Thrombolysis Administration Times Before And After Tenecteplase Implementation Across Different Hospital Types (Hall F, Poster Hall; P42) - Feb 7, 2023 - Abstract #ISC2023ISC_1548;
However, more trials are needed to further compare both approaches and to evaluate the impact of certain factors on this comparison such as MT technique (Stent Retriever versus Aspiration), LVO location, and the used thrombolytic agent (Alteplase versus Tenecteplase). For the first 6 months of tenecteplase implementation the DTN time increased at FSEDs and PSCs but remained unchanged in higher volume centers.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrolling Patients During Covid-19: Lessons From The Timeless Clinical Trial (Hall F, Poster Hall; P30) - Feb 7, 2023 - Abstract #ISC2023ISC_1536;
P3
The TIMELESS trial (NCT03785678) is a Phase III study to determine whether tenecteplase treatment increases the proportion of good clinical outcomes in patients with acute ischemic stroke who present 4.5-24 hours after symptom onset...These challenges, while exacerbated by COVID-19, are relevant beyond the pandemic and acute stroke trials. The lessons and experiences of successful sites show that successful clinical trial enrollment requires clear channels of communication, collaboration with nonresearch stakeholders, and an engaged research team with well-defined roles who are committed to integrating research plans into each site’s clinical workflows.
|
